KLK5 as a Biomarker for Breast Cancer Diagnosis
Author Information
Author(s): Avgeris Margaritis, Papachristopoulou Georgia, Polychronis Athanasios, Scorilas Andreas
Primary Institution: Department of Biochemistry and Molecular Biology, University of Athens
Hypothesis
Can KLK5 expression levels differentiate between malignant and benign breast lesions?
Conclusion
KLK5 expression quantification may serve as a novel and independent biomarker for distinguishing malignant from benign breast tumors.
Supporting Evidence
- KLK5 expression was significantly lower in malignant breast tissues compared to benign ones.
- The study used logistic regression and ROC analysis to evaluate KLK5's diagnostic potential.
- A significant correlation was found between KLK5 levels and pre-menopausal status.
- KLK5 expression levels were also associated with estrogen receptor negativity.
Takeaway
This study found that lower levels of a protein called KLK5 in breast tissue can help doctors tell if a tumor is cancerous or not.
Methodology
KLK5 expression levels were measured in 102 breast tissue samples using RT-qPCR and analyzed with advanced biostatistics.
Participant Demographics
69 malignant and 33 benign breast tissue specimens from patients who had not received prior hormonal therapy or chemotherapy.
Statistical Information
P-Value
p < 0.001
Confidence Interval
95% CI: 0.32 - 0.68
Statistical Significance
p < 0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website